A Randomized Phase I, Double-Blind, Parallel, Comparative Assessment of Pharmacokinetics, Safety, Pharmacodynamics, and Immunogenicity of LT-01 (an Omalizumab Biosimilar Candidate [Test]) Lyophylized Powder for Subcutaneous Injection Versus Eu-Approved Xolair® Lyophylized Powder for Subcutaneous Injection (Reference) in Healthy Subjetcs: Cima Study.

2023-505908-28-00 Protocol LT-02-19 Human pharmacology (Phase I) - Bioequivalence study Ended

Start 26 Feb 2025 · End 5 Jan 2026 · Status Ended · 1 EU/EEA countries · 2 sites · Protocol LT-02-19

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Bioequivalence study
Status Ended
Participants planned 128
Countries 1
Sites 2

Chronic spontaneous urticaria

Key facts

Sponsor
Laboratorios Liomont S.A. de C.V.
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Immune System Diseases [C20]
Trial duration
26 Feb 2025 → 5 Jan 2026
Decision date (initial)
2025-01-15
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Chronic spontaneous urticaria

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Laboratorios Liomont S.A. de C.V.

Sponsor organisation
Laboratorios Liomont S.A. de C.V.
Address
Calle Adolfo Lopez Mateos 68, Col. Cuajimalpa Col. Cuajimalpa
City
Ciudad De Mexico
Postcode
05000
Country
Mexico

Scientific contact point

Organisation
Laboratorios Liomont S.A. de C.V.
Contact name
Livan Delgado

Public contact point

Organisation
Laboratorios Liomont S.A. de C.V.
Contact name
Livan Delgado

Locations

1 EU/EEA country · 2 investigational sites

By country

CountryMS statusPlanned subjectsSites
Spain Ended 68 2
Rest of world
Mexico
60

Investigational sites

Spain

2 sites · Ended
Hospital Del Mar
Pharmacology, Passeig Maritim De La Barceloneta 25-29, 08003, Barcelona
Hospital De La Santa Creu I Sant Pau
Pharmacology, Calle De San Antonio Maria Claret 167, 08025, Barcelona

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Spain 2025-02-26 2025-11-13 2025-03-07 2025-07-09

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-09-27 Spain Acceptable
2025-01-15
2025-01-15
2 NON SUBSTANTIAL MODIFICATION NSM-3 2025-03-05 Spain Acceptable
2025-01-15
2025-03-05
3 SUBSTANTIAL MODIFICATION SM-1 2025-04-03 Spain Acceptable
2025-05-17
2025-05-17